Trial · NCT03606408
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Adverse events (AEs) | 115 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Treatment-related AEs | 50 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Adverse events of CTCAE Grade ≥ 3 | 34 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Treatment-related AEs of CTCAE Grade ≥ 3 | 3 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Serious adverse events | 35 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Treatment-related SAEs | 4 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Fatal SAEs | 2 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Treatment-related fatal SAEs | 0 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Adverse events leading to discontinuation | 14 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Treatment-related AEs leading to discontinuation | 5 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Adverse events leading to dose interruption or adjustment | 56 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Treatment-related AEs leading to dose interruption or adjustment | 35 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Adverse events requiring additional therapy | 94 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Treatment-related AEs requiring additional therapy | 17 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Adverse events of special interest (AESIs) | 51 | Participants | |
| Number of Participants With Adverse/Serious Adverse Events | Osilodrostat | Treatment-related AESIs | 29 | Participants | |
| Percentage of Patients With Clinical Benefit | Osilodrostat | Week 1 | 127 | Participants | |
| Percentage of Patients With Clinical Benefit | Osilodrostat | Week 12 | 122 | Participants | |
| Percentage of Patients With Clinical Benefit | Osilodrostat | Week 24 | 119 | Participants | |
| Percentage of Patients With Clinical Benefit | Osilodrostat | Week 36 | 114 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03606408/results